Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc7.2 | Cardiovascular endocrinology (1) | ECE2017

Targeted molecular markers derived from genomic classification for adrenocortical cancer prognostication

Jouinot Anne , Assie Guillaume , Fassnacht Martin , Libe Rossella , Dousset Bertrand , Ronchi Silviu Sbiera Cristina , Kroiss Matthias , Korpershoek Esther , De Krijger Ronald , Waldmann Jens , Quinkler Marcus , Tabarin Antoine , Chabre Olivier , Luconi Michaela , Mannelli Massimo , Groussin Lionel , Baudin Eric , Amar Laurence , Beuschlein Felix , Bertherat Jerome

Background: Adrenocortical cancer (ACC) is an aggressive tumour with heterogeneous prognosis. Recently integrated genomics reported distinct genomic alterations: transcriptome “C1A” (high expression of proliferation/cell cycle-related genes) vs “C1B”, “CIMP” (CpG islands hypermethylation) vs “non-CIMP”, chromosome alterations “Noisy” (numerous and anarchic alterations) vs “Chromosomal” (extended patterns of loss of he...

ea0041oc1.2 | Adrenal - Basic & Clinical | ECE2016

Focal DNA methylation measurement in adrenocortical carcinoma is a prognostic marker independent from tumor stage and Ki67; an ENSAT study

Assie Guillaume , Jouinot Anne , Libe Rossella , Fassnacht Martin , Sbiera Silviu , Ronchi Cristina , De Krijger Ronald , Waldmann Jens , Quinkler Marcus , Tabarin Antoine , Chabre Olivier , Mantero Franco , Mannelli Massimo , Kerlan Veronique , Groussin Lionel , Baudin Eric , Beuschlein Felix , Clauser Eric , Coste Joel , Bertherat Jerome

Recent pan-genomic analyses of tumor DNA identified specific patterns of DNA methylation –e.g. CpG islands hypermethylation in the promoter regions of genes- as pejorative prognostic markers in adrenocortical cancer (ACC). Integrated genomics clearly shows that ACC with such an hypermethylation belongs to specific subgroups of ACC with increased driver genes alterations and a poor survival.Aim: To confirm the prognostic value of this methylation pat...

ea0070oc7.1 | Endocrine-related Cancer | ECE2020

Is Carney complex a breast cancer predisposing syndrome? prospective study of 50 women

Vaduva Patricia , Espiard Stéphanie , Jouinot Anne , Vantyghem Marie-Christine , Assié Guillaume , Catherine Cardot-Bauters , Raverot Gerald , Sylvie Hieronimus , Francoise Archambeaud , Hervé Lefebvre , Laure Nunes , Tabarin Antoine , Anne Lienhardt , Groussin Lionel , Guignat Laurence , Fideline Bonnet , North Marie-Odile , Bertherat Jerome

Introduction: Carney Complex (CNC) is a rare genetic syndrome, with multiple endocrine and non-endocrine neoplasia, mostly due to inactivating mutations of the PRKAR1A gene. CNC has a wide spectrum of manifestations : most frequently skin lesions, cardiac myxomas and primary pigmented nodular adrenocortical dysplasia (PPNAD), but also thyroid nodules, schwannomas, breast tumors (mainly myxoid fibroadenomas and ductal adenomas)… The present study was designed to ...

ea0070aep596 | Pituitary and Neuroendocrinology | ECE2020

Efficacy and safety of long-acting pasireotide (LA-PAS) in patients with uncontrolled acromegaly: Results from the prospective cohort of european observational acronis study

Pivonello Rosario , Tabarin Antoine , Colao Annamaria , Kaltsas Gregory , Gonzalez-Molero Inmaculada , Neggers Sebastian , Venegas Moreno Eva , Kocjan Tomaz , Karges Wolfram , Krzyzanowska-Mittermayer Katarzyna , Heck Ansgar , Eden Engstrom Britt , Marques Ruben , O’Brien Eamonn , Manne Shobha , Vincenzi Beatrice , Schöfl Christof

Introduction: Results of the first European real-world evidence from retrospective cohort of ACRONIS study previously confirmed the efficacy and tolerability of LA-PAS in heavily pre-treated, uncontrolled acromegaly patients. Here, we report results of the second interim analysis reflecting the prospective cohort.Methods: Patients who were treated with LA-PAS for ≥6 months were included in this analysis. The primary objective was to document treatm...

ea0032oc4.3 | Adrenal | ECE2013

Prognostic factors of advanced unresectable by stage III and IV ENS@T adrenocortical carcinomas (ACC)

Libe Rossella , Borget Isabelle , Ronchi Cristina , Terzolo Massimo , Haaf Michaela , Laino Federica , Kherkhof Thomas , Corsini Elisa , Tabarin Antoine , Chabre Olivier , De la Fouchardiere Christelle , Niccoli Patricia , Caron Philippe , Mannelli Massimo , Haak Harm , Beuchlein Felix , Bertherat Jerome , Berruti Alfredo , Fassnacht Martin , Baudin Eric

Introduction: The prognosis of stages III–IV ACC patients is dismal. The 5-year survival of stage IV ACC ranges between 0 and 13% and no prognostic study has focused on stage III, yet. Several reports suggest a greater heterogeneity of advanced ACC prognosis that initially thought.Aim: The primary objective of our study was to analyse the prognostic factors of overall survival of the subgroup of advanced unresectable stage III–IV ACC patients c...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage III–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...

ea0056oc12.5 | Novel aspects of puberty development and Cushing's disease | ECE2018

Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing’s syndrome. Data from ERCUSYN

Valassi Elena , Tabarin Antoine , Brue Thierry , Feelders Richard A , Reincke Martin , Neteia-Maier Romana , Toth Miklos , Yaneva Maria , Webb Susan M , Tsagarakis Stylianos , Chanson Philippe , Pfeifer Marija , Droste Michael , Komerdus Irina , Kastelan Darko , Maiter Dominique , Chabre Olivier , Franz Holger , Santos Alicia , Strasburger Christian J , Trainer Peter J , Newell-Price John , Ragnarsson Oskar

Background: Patients with active Cushing’s syndrome (CS) have increased mortality.Aims: Evaluate cause of death in a large cohort of CS patients, and establish factors associated with increased mortality.Methods: We analysed 1514 patients included in the European Registry on Cushing’s syndrome (ERCUSYN): 1022 (68%) had pituitary-dependent CS (PIT-CS), 379 (25%) adrenal-dependent CS (ADR-CS), 71 (5%) had an ectopic source ...

ea0073oc1.3 | Oral Communications 1: Adrenal and Cardiovascular Endocrinology | ECE2021

PDE11A4 (Phosphodiesterase 11 A4) is a modulator of the primary bilateral macronodular adrenal hyperplasia (PBMAH) phenotype: genotype/phenotype analysis of a cohort of 354 patients analysed by next-generation sequencing (NGS)

Vaduva Patricia , Anna Vaczlavik , Lucas Bouys , Neou Mario , Septier Amandine , Heurtier Victor , Cavalcante Isadora Pontes , RossellaLibe , Fabio Faucz , Gaetan Giannone , Kroiss Matthias , Borson-Chazot Francoise , Chanson Philippe , Tabarin Antoine , Marie-Christine Marie-Christine , Assié Guillaume , Candida Barisson Villares Fragoso Maria , Constantine Stratakis , Ragazzon Bruno , Bertherat Jerome

IntroductionPrimary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of adrenal Cushing’s syndrome due to bilateral adrenal tumors, is an heterogenous disease with various clinical, hormonal and morphological characteristics. ARMC5 inactivating mutations is the most frequent genetic cause of PBMAH and variants of PDE11A4 have been associated with the disease. In order to better understand the heterogeneity ...

ea0073pep11.6 | Presented ePosters 11: Adrenal and Cardiovascular Endocrinology | ECE2021

Increased risk of cardiometabolic disease in patients with benign adrenal tumours with and without cortisol excess: a case–control study

Prete Alessandro , Subramanian Anuradhaa , Bancos Irina , Sitch Alice J , Chortis Vasileios , Lang Katharina , Tsagarakis Stylianos , Macech Magdalena , Delivanis Danae A , O’Reilly Michael W , Masjkur Jimmy R , Quinkler Marcus , Ueland Grethe Å , Dennedy M Conall , Beuschlein Felix , Tabarin Antoine , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Kastelan Darko , Young William F Jr , Manolopoulos Konstantinos N , Ambroziak Urszula , Vassiliadi Dimitra A , Nirantharakumar Krishnarajah , Arlt Wiebke

BackgroundBenign adrenocortical tumours are found in 3–5% of adults and can be non-functioning (NFAT) or associated with cortisol excess. The latter group divides into patients with clinically overt signs (adrenal Cushing’s syndrome, CS) and patients lacking CS signs (mild autonomous cortisol excess, MACE). The 1 mg-overnight dexamethasone suppression test (DST) further differentiates MACE into MACE-1 (possible MACE; post-DST cortisol 50–1...